<DOC>
	<DOC>NCT02637141</DOC>
	<brief_summary>Protocol CELIM-NRCD-001 is designed to be a Phase 2a, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of AMG 714 for the attenuation of the effects of gluten exposure in adult patients with celiac disease during a gluten challenge.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Diagnosis of celiac disease by intestinal biopsy at least 12 months prior to screening On a glutenfree diet for at least 12 months Negative celiac serology Avoidance of pregnancy Severe complications of celiac disease, such as refractory celiac disease Celiac symptoms Other concomitant autoimmune disease Chronic, active GI disease Infections, concomitant diseases Prohibited medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>celiac</keyword>
	<keyword>gluten</keyword>
	<keyword>IL-15</keyword>
	<keyword>AMG 714</keyword>
</DOC>